Spindle Cell Sarcoma — Variants & evidence

Spindle Cell Sarcoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Fusion2
Bevacizumab + Sorafenib + TemsirolimusCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID1664 A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC) PMID 24422672 · Subbiah et al., 2014 · Open in CIViC	civic
〃	Predictive	C	Supports Sensitivity Response	2	accepted	EID7312 A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic
NTRK1 Fusion1
TRK Inhibitor	Predictive	C	Supports Sensitivity Response	3	accepted	EID8902 A 40-year-old patient with a left calf mass revealed by biopsy to be a low grade myxoid spindle cell carcinoma underwent surgery and radiotherapy. Over a 5-year period, the patient experienced 3 lung … (full text at CIViC) PMID 32050835 · So et al., 2020 · Open in CIViC	civic
RAF1 Fusion1
Trametinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID10326 Case report of a 27-year old female patient with spindle cell sarcoma. Initial treatment consisted of eight cycles of alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide plus… (full text at CIViC) PMID 35050712 · Panet et al., 2022 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7419 In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.